ClinicalTrials.gov
ClinicalTrials.gov Menu

The Use of Oracea and Epiduo Forte in Severe Acne Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03457636
Recruitment Status : Active, not recruiting
First Posted : March 7, 2018
Last Update Posted : November 2, 2018
Sponsor:
Information provided by (Responsible Party):
Derm Research, PLLC

Brief Summary:
This is a single-center, open label pilot study. The study is comprised of 5 study visits; Screening, Baseline, and weeks 4, 8, and 12. All subjects will receive Oracea once daily (QD) and Epiduo Forte at Baseline. We will evaluate Investigator Global Assessment (IGA), total lesion count, inflammatory lesion count, non-inflammatory lesion count, adverse events and concomitant medications.

Condition or disease Intervention/treatment Phase
Acne Drug: Doxycycline Anhydrous 40 MG Drug: Adapalene-Benzoyl Peroxide Gel 0.3-2.5% Phase 4

Detailed Description:
This is a single-center, open label pilot study. The study is comprised of 5 study visits; Screening, Baseline, and weeks 4,8, and 12. All subjects will receive Oracea once daily (QD) and Epiduo Forte at Baseline. WE will evaluate Investigator Global Assessment (IGA), total lesion count, adverse events and concomitant medications.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 22 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Use of Oracea and Epiduo Forte in Severe Acne Patients
Actual Study Start Date : March 19, 2018
Estimated Primary Completion Date : December 2018
Estimated Study Completion Date : January 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Acne

Arm Intervention/treatment
Experimental: doxycycline anhydrous 40 mg once daily and adapalene/benzoyl p
All subjects will receive at Baseline doxycycline anhydrous 40 mg and Adapalene-Benzoyl Peroxide Gel .3-2.5% (Epiduo) to be applied once daily
Drug: Doxycycline Anhydrous 40 MG
One Oracea Capsule (40 mg) should be taken once daily in the morning on an empty stomach, preferably at least one hour prior to or two hours after meals
Other Name: Oracea

Drug: Adapalene-Benzoyl Peroxide Gel 0.3-2.5%
Epiduo Forte should be applied in a thin layer to affected areas of the face and/or trunk once daily after washing, with care taken to avoid the eyes, lips, and mucous membranes
Other Name: Epiduo Forte 0.3%-2.5% Topical Gel




Primary Outcome Measures :
  1. Investigator Global Assessment (IGA) score [ Time Frame: 12 weeks ]
    The percentage of patients who become clear or almost clear on the IGA scale


Secondary Outcome Measures :
  1. IGA score [ Time Frame: 12 weeks ]
    The percent of subjects who have at least a 2 grade or more improvement on IGA score

  2. Inflammatory, non-inflammatory and total lesion count [ Time Frame: 12 weeks ]
    Median percent reduction in inflammatory, non-inflammatory and total lesion count



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   12 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

i. Outpatient, male or female subjects of any race, and at least 12 years of age or older. Female subjects of childbearing potential must have a negative urine pregnancy test result at Baseline (test must have a sensitivity of at least 25 milli-international units/milliliter [mIU/ml] for human chorionic gonadotropin) and practice a reliable method of contraception throughout the study:

A female is considered of childbearing potential unless she is:

  • postmenopausal for at least 12 months prior to study drug administration;
  • without a uterus and/or both ovaries; or
  • has been surgically sterile for at least 6 months prior to study drug administration

Reliable methods of contraception are:

  • hormonal methods or intrauterine device in use ≥90 days prior to study drug administration;
  • barrier methods plus spermicide in use at least 14 days prior to study drug administration; or
  • vasectomized partner (vasectomy must be performed 3 months prior to first study drug administration or in the alternative a zero sperm count will suffice) [Exception: female subjects of childbearing potential who are not sexually active will not be required to practice a reliable method of contraception. These subjects may be enrolled at the Investigator's discretion if they are counseled to remain sexually inactive during the study and understand the possible risks in getting pregnant during the study.] ii. Facial acne IGA score of 4 iii. Minimum of 20 or more inflammatory lesions and 20 or more non-inflammatory lesions and not more than 4 nodules iv. Able to understand the requirements of the study and sign Informed Consent/HIPAA Authorization forms. Subjects under the legal age of consent in the state where the study is conducted must also have the written, informed consent of a parent or legal guardian

Exclusion Criteria:

i. Female subjects who are pregnant (positive urine pregnancy test ), breast-feeding, or who are of childbearing potential and not practicing a reliable method of birth control ii. Allergy or sensitivity to any component of the test medication iii. Subjects who have not complied with the proper wash-out periods for prohibited medications (Supplement I)> iv. Medical condition that, in the opinion of the investigator, contraindicates the subject's participation in the clinical study v. Skin disease/disorder that might interfere with the diagnosis or evaluation of acne vulgaris vi. Evidence of recent alcohol or drug abuse vii. History of poor cooperation, non-compliance with medical treatment, or unreliability viii. Exposure to an investigational drug study within 30 days of the Baseline Visit -


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03457636


Locations
United States, Kentucky
Skin Sciences, PLLC
Louisville, Kentucky, United States, 40014
Sponsors and Collaborators
Derm Research, PLLC
Investigators
Principal Investigator: Leon H. Kircik, M.D. Skin Sciences, PLLC

Responsible Party: Derm Research, PLLC
ClinicalTrials.gov Identifier: NCT03457636     History of Changes
Other Study ID Numbers: ORA-1801
First Posted: March 7, 2018    Key Record Dates
Last Update Posted: November 2, 2018
Last Verified: November 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Additional relevant MeSH terms:
Doxycycline
Benzoyl Peroxide
Adapalene
Adapalene, Benzoyl Peroxide Drug Combination
Anti-Bacterial Agents
Anti-Infective Agents
Antimalarials
Antiprotozoal Agents
Antiparasitic Agents
Dermatologic Agents
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents